IP Library Granted Patent US 9,138,466
Granted Patent B2
US 9,138,466 · App. 14/210,076 · Granted Sep 22, 2015

Factor H for transplantation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,138,466
App. No.
14/210,076
Granted
Sep 22, 2015
Kind
B2
Abstract

The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H.

Claims (14)

1. A method for inhibiting allograft rejection by a recipient of said allograft, said method comprising treating said recipient with a composition comprising Factor H (FH), sirolimus (Rapamycin) and FK506 (FK).

2. The method of claim 1 , wherein said FH is plasma-derived FH or recombinant FH.

3. The method of claim 1 , wherein said allograft rejection is an antibody mediated rejection or a combination of antibody and cell mediated rejection.

4. The method of claim 1 , wherein said inhibiting allograft rejection comprises prolonging allograft survival and/or function for a predetermined number of days.

5. The method of claim 1 , wherein said inhibiting allograft rejection comprises preventing or inhibiting an increase in levels of markers of allograft rejection.

6. The method of claim 1 , wherein said allograft rejection is acute antibody-mediated rejection.

7. The method of claim 5 , wherein said recipient is treated with the composition upon receipt of said allograft until said allograft functions normally.

8. The method of claim 6 , wherein normal function of said allograft is determined by recipient creatinine level and/or negative C4d biopsy testing.

9. The method of claim 1 , wherein said allograft rejection occurs 3-6 months after receipt of said allograft.

10. The method of claim 1 , wherein said allograft comprises an organ.

11. The method of claim 10 , wherein said organ is a whole organ.

12. The method of claim 11 , wherein said whole organ is a member selected from kidney, heart, liver, intestine, pancreas and lung.

13. The method of claim 1 , wherein said allograft comprises tissue.

14. The method of claim 1 , wherein said allograft is a member selected from a skin graft, a bone graft, a valve, and bone marrow.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036372/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: JOHNSON, RICHARD; ZHANG, ZHENG JENNY
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 033435/0316 →